Table 3.
Best response and duration of response to blinatumomab in 12 long-term survivors
| Patient | Histology | No. of prior therapies | Dose, µg/m2 per d | Duration of treatment, d | Best response | OS, d | PFS, d | TFS, d |
|---|---|---|---|---|---|---|---|---|
| 47 | FL | 2 | 30 | 55 | SD | 3887 | 73 | 212 |
| 48 | FL | 1 | 60 | 55 | CR | 3677 | 234 | 246 |
| 66 | FL | 3 | 60 | 57 | CR | 2592 | 336 | 576 |
| 67 | MCL | 2 | 60 | 58 | CR | 3320 | 1180 | 1365 |
| 68 | FL | 3 | 60 | 15 | SD | 2690 | 613 | 643 |
| 70 | FL | 3 | 60 | 57 | CR | 2844 | 1466 | 1650 |
| 71* | FL | 3 | 60 | 85 | PR | 3775 | 3775 | 3775 |
| 72* | FL | 1 | 60 | 35 | PR | 3649 | 3649 | 3649 |
| 73* | MCL | 3 | 90 | 57 | CR | 3215 | 3215 | 3215 |
| 74* | FL | 1 | 60 | 57 | PR | 3005 | 3005 | 3005 |
| 75* | DLBCL | 3 | 60 | 56 | CR | 2816 | 2816 | 2816 |
| 76* | MCL | 1 | 60 | 57 | CR | 2816 | 2816 | 2816 |
*
OS >5 years; patients are in ongoing remission.